RecruitingPhase 1NCT03633955

Pilot Imaging Study of Leukemia

Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging

Sponsor

University of Oklahoma

Enrollment

60 participants

Start Date

Jan 19, 2023

Study Type

INTERVENTIONAL

Conditions

Acute Myeloid Leukemia Myeloma Acute Lymphocytic Leukemia Ambiguous Lineage Leukemia or Lymphoma

Summary

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

Eligibility

Min Age: 4 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This pilot imaging study is using a special PET scan with a tracer called 18F-FLT — which highlights areas where cells are rapidly dividing — to better map the spread of leukemia throughout the body in patients with high-risk blood cancers that have not responded to treatment. **You may be eligible if...** - You are between 4 and 80 years old - You have been diagnosed with a high-risk blood cancer that has relapsed or is not responding to treatment (such as acute lymphocytic leukemia, acute myeloid leukemia, ambiguous lineage leukemia, or myeloma) - You are in reasonably good health (Karnofsky/Lansky score of 50 or above) - Your liver and kidney function tests are within acceptable ranges - You are able to undergo the PET imaging without sedation **You may NOT be eligible if...** - You have serious liver or kidney problems - You require sedation to undergo imaging - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFLT

F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.

Locations(3)

Children's National Health System

Washington D.C., District of Columbia, United States

Emory University

Atlanta, Georgia, United States

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03633955

Related Trials

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649220 locations

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390346 locations

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT05554406220 locations

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393177 locations

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT0495389721 locations